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Part I 
 
Differential mitotic activation of endogenous c-Src,  
c-Yes, and Lyn in HeLa cells 
 
Abstract 
Src-family tyrosine kinases (SFKs) play an important role in mitosis. Despite overlapping 
expression of multiple SFK members, little is known about how individual SFK members are 
activated in M phase. Here, we examined mitotic activation of endogenous c-Src, c-Yes, and Lyn, 
which are co-expressed in HeLa cells. c-Src, c-Yes, and Lyn were activated at different levels in 
M phase, and the activation was inhibited by Cdc2 inactivation. Mitotic c-Src and c-Yes 
exhibited normal- and retarded-electrophoretic-mobility forms on SDS–polyacrylamide gels, 
whereas Lyn did not show mobility retardation. Like c-Src, the retardation of electrophoretic 
mobility of c-Yes was caused by Cdc2-mediated phosphorylation. The normal- and 
retarded-mobility forms of c-Src were comparably activated, but activation of the 
retarded-mobility form of c-Yes was higher than that of the normal-mobility form of c-Yes. Thus, 
these results suggest that endogenous c-Src, c-Yes, and Lyn are differentially activated through 
Cdc2 activation during M phase. 
 
 
Introduction 
Src-family tyrosine kinases (SFKs), a group of non-receptor-type tyrosine kinases, include 
at least eight members: c-Src, c-Yes, Lyn, Fyn, Lck, Hck, Blk, and c-Fgr. SFKs are known to 
play crucial roles in regulating proliferation, differentiation, and cytoskeletal alterations [1,2]. 
c-Src, c-Yes, Lyn, and Fyn are widely expressed in a variety of cell types, whereas Blk, c-Fgr, 
Hck, and Lck are found primarily in hematopoietic cells [2,3]. Multiple members of SFKs are 
co-expressed in all cell types, and there is considerable redundancy in activation of SFK 
members [2]. 
SFKs are composed of: a Src homology (SH) 4 domain, a poorly conserved “unique” 
domain, an SH3 domain, an SH2 domain, an SH1 tyrosine kinase catalytic domain, and a 
C-terminal inhibitory tail [1]. The SH4 domain, which contains a site(s) for acylation such as 
myristoylation and palmitoylation, is a membrane-targeting region [4]. The sequences of the 
unique domain are divergent among SFKs and contain many phosphorylation sites for Ser/Thr 
kinases [5–9]. The SH2 and SH3 domains can mediate specific protein–protein interactions [1,2]. 
 6 
Activated SFKs are autophosphorylated at Tyr419 in the activation loop of the kinase 
domain (numbering for human c-Src with the initiator methionine) [1,2], and SFK 
autophosphorylation shows full catalytic activity [10]. Phosphorylation at Tyr530, however, 
promotes the assembly of the SH2, SH3 and kinase domains into an inactive conformation 
[11,12].  
There is accumulating evidence that SFKs play a regulatory role in mitosis. Kinase activity 
of c-Src increases in M phase and decreases in interphase [13]. Treatment with SFK inhibitors 
blocks metaphase progression [14,15] and cytokinesis [16,17]. Microinjection of the cst.1 
neutralizing antibody specific for c-Src, c-Yes and Fyn, or the SH2 domain of c-Src or Fyn 
prevents G2/M transition and cytokinesis [16,18,19]. In addition, c-Yes and Fyn are activated 
during M phase in c-Yes- or Fyn-overexpressor cells, and c-Src, c-Yes, and Fyn are suggested to 
play a redundant role in regulating G2/M transition [18]. However, little is known about how 
individual members of endogenous SFKs are activated in M phase. 
In this report, we examined the relationship between mitotic activation of endogenous 
c-Src, c-Yes, and Lyn, which are co-expressed in HeLa cells, and their electrophoretic mobility. 
Our results show that c-Src, c-Yes, and Lyn are differentially activated through Cdc2 activation 
during M phase. 
 
 
Materials and methods 
Cells and cell culture 
HeLa (Japanese Collection of Research Bioresources), HEK293 (provided by M. Tagawa), 
A431 and HT-H (provided by M.N. Fukuda) [20,21], NIH3T3 (provided by K. Igarashi), and 
COS-1 cells were cultured in Iscove’s modified Dulbecco’s medium containing 5% fetal bovine 
serum. Transient transfection was performed using TransIT transfection reagent (Mirus) [22]. 
SFK and Cdc2 kinase activities were specifically inhibited by 5 µM PP2, an SFK inhibitor [23], 
and 50 µM roscovitine, a cyclin-dependent kinase inhibitor [24], respectively. 
 
Antibodies 
The following monoclonal antibodies were used: c-Src [Src(327); Oncogene Research, and 
Src(GD11); Upstate Biotechnology, Inc.], Lyn [Lyn(H-6); Santa Cruz Biotechnology], c-Yes 
[Yes(1); BD Biosciences], Fyn [Fyn(301); Wako Pure Chemicals, Osaka], phosphotyrosine 
(pTyr, 4G10; Upstate Biotechnology, Inc), Cdc2 (clone 17; Santa Cruz Biotechnology), lamin 
B1 (L-5; Zymed), FLAG (BioM2; Sigma), and α-tubulin (MCA78G; Serotec). The following 
rabbit polyclonal antibodies were used: cyclin B1 (H-433; Santa Cruz Biotechnology), Lyn 
[Lyn(44); Santa Cruz Biotechnology], Fyn [Fyn(3); Santa Cruz Biotechnology], GFP (A.v. 
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peptide antibody to GFP; Clontech), and Src[pY418] (BioSource International). Anti-Src[pY418] 
antibody recognizes autophosphorylation of c-Src at Tyr419, c-Yes at Tyr426, 56 kDa Lyn at 
Tyr397 and 53 kDa Lyn at Tyr376 (two alternative spliced isoforms of Lyn), and Fyn at Tyr420 
[17,22,25]. FITC-F(ab’)2 of anti-mouse IgG (BioSource International) and anti-rabbit IgG 
(Sigma) antibodies were used. Horseradish peroxidase-F(ab’)2 of anti-mouse IgG, anti-rabbit Ig 
and anti-rat Ig antibodies (Amersham Biosciences) were used. 
 
Plasmids 
Cyclin B1(R42A)-GFP, a green fluorescent protein-tagged (GFP-tagged) non-degradable 
human cyclin B1 mutant, subcloned into the pCMX vector was provided by J. Pines [26]. 
FLAG-tagged human Cdc2 [Flag-Cdc2(AF)], of which Thr14 and Tyr15 residues are mutated 
respectively to alanine and phenylalanine in the pUHD-P1 vector, was provided by R.Y.C. Poon 
[27]. Human c-Src cDNA was provided by D.J. Fujita [28], and cDNAs of human c-Yes [29], 
Lyn [30], and Fyn [31] were provided by T. Yamamoto. c-Src and Lyn were subcloned into 
pcDNA4/TO vector (Invitrogen) as described [22,32], and c-Yes and Flag-Cdc2(AF) were also 
subcloned into the pcDNA4/TO vector. 
 
Cell cycle synchronization 
For S-phase arrest, cells were treated with 1 µg/ml aphidicolin for 24 h. For G2/M arrest, 
S-phase-arrested cells were washed free of aphidicolin and incubated with 0.1 µg/ml nocodazole 
for further 16 h. Detached, round-shaped cells (M phase) were isolated by flushing, and the 
remaining spreading cells, which adhered to culture dishes, were collected as G2-phase cells. For 
M → G1 progression, nocodazole-arrested cells were washed free of nocodazole and then 
cultured in fresh medium for further 1–3 h. To obtain M-phase cells not exposed to nocodazole, 
round-shaped cells were isolated by multiple rounds (30–60 min intervals) of flushing from cells, 
which were released from S-phase arrest and cultured for further 10–13 h in the absence of 
nocodazole. Cell cycle phase was examined by flow cytometry using an EPICS ELITE flow 
cytometer (Beckman Coulter) or a MoFlo cell sorter (Dako Cytomation, TakaraBio, Inc.) as 
described [33]. 
 
Immunofluorescence 
Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 min at 
room temperature, permeabilized in PBS containing 0.1% saponin and 3% bovine serum 
albumin for 1 h, and stained with appropriate antibodies as described [32,34,35]. F-actin was 
stained with rhodamine-phalloidin as described [36]. DNA was stained with 100 µg/ml 
propidium iodide for 30 min after treatment with 200 µg/ml RNase A [37] or with 10 µg/ml 
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4',6-diamidino-2-phenylindole (DAPI). Stained cells were viewed under a Fluoview FV500 
confocal laser scanning microscope (Olympus, Tokyo).  
 
Western blotting and immunoprecipitation 
For Western blotting, cells were lysed in SDS–PAGE sample buffer or Triton X-100 lysis 
buffer [TX100; 1% Triton X-100, 50 mM Hepes–KOH, pH 7.4, 10% glycerol, 100 mM NaF, 5 
µM ZnCl2, 10 mM Na3VO4, 50 µg/ml aprotinin, 100 µM leupeptin, 25 µM pepstatin A, and 2 
mM phenylmethylsulfonyl fluoride (PMSF)], and the remaining TX100-insoluble pellets were 
lysed in SDS–PAGE sample buffer. For immunoprecipitation, cells were lysed in Empigen lysis 
buffer [0.5% Empigen BB (Calbiochem), 50 mM Hepes–NaOH, pH 7.2, 5 µM ZnCl2, 100 mM 
NaF, 2 mM EGTA, 10% glycerol, 50 µg/ml aprotinin, 100 µM leupeptin, 25 µM pepstatin A, 2 
mM PMSF, and 10 mM Na3VO4] containing 20 mM β-glycerophosphate, 30 mM sodium 
pyrophosphate and 10 mM Hepes (Figs. 1.2, 1.3 and 1.6, and Supplementary Fig. 1.2B), or 
containing 50 mM β-glycerophosphate and 60 mM Hepes (Supplementary Fig. 1.1F-b and 1.4). 
Empigen BB is capable of solubilizing a large fraction of both TX100-soluble and -insoluble 
proteins [38]. Empigen-solubilized cell fractions were reacted with protein G-Sepharose 
precoated with an antibody for 3 h at 4°C [34,39]. Anti-Src(327), anti-Lyn(H-6), anti-Yes(1), or 
anti-Fyn(301) antibody was used for immunoprecipitation. Lysates (4 x 104 cells/lane) and 
immunoprecipitates (2 x 106 cells/lane) were analyzed by SDS–PAGE and Western blotting 
using the enhanced chemiluminescence (ECL) detection system (GE Healthcare) as described 
[40,41]. Sequential reprobing of membranes with appropriate antibodies was performed as 
described [42]. Intensity of chemiluminescence was measured using the ImageJ software 
(National Institutes of Health). 
 
Treatment with alkaline phosphatase 
Immunoprecipitates were treated with or without 40 units of calf intestinal alkaline 
phosphatase (CIAP; New England Biolabs) for 2 h at 37°C in alkaline buffer [50 mM Tris–HCl, 
pH 9.0, 1 mM MgCl2, 1 mM DTT, and 0.5% SDS] in the presence or absence of 3 mM Na3VO4, 
a CIAP inhibitor [43]. The reactions were terminated by boiling in SDS–PAGE sample buffer. 
For adjusting the loading conditions, CIAP-untreated samples dissolved in SDS–PAGE sample 
buffer were supplemented with CIAP just before boiling. 
 
 
Results 
Activation of c-Src, c-Yes, and Lyn in M phase 
To examine activation states of SFK members in M phase, we synchronized HeLa cells at 
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M phase with aphidicolin and nocodazole. Aphidicolin-arrested S-phase cells were released and 
synchronized at G2/M phase by nocodazole, and then nocodazole-arrested cells were released for 
exit from M phase to the next cell cycle (Fig. 1.1A). M-phase cells were judged on the following 
criteria: (i) 4N DNA content (Fig. 1.1A), (ii) expression of cyclin B1, a marker of G2/M phase 
(Fig. 1.1C) [26], and (iii) round-shaped cell morphology (Fig. 1.1B and C). As shown in Fig. 1.1, 
the number of M-phase cells was increased during 9–16 h after S-phase release, peaked at 16 h, 
and gradually decreased after nocodazole release because of entry into the next cell cycle. 
c-Src, c-Yes, Lyn (Lyn53 and Lyn56: two alternative spliced isoforms at 53 and 56 kDa), 
and Fyn were found to widely co-express in epithelial and fibroblastic cells (Supplementary Fig. 
1.1). To examine whether all of these SFK members were activated in M phase, they were 
immunoprecipitated from lysates of M- and G2-phase HeLa cells and analyzed for active, 
autophosphorylated SFKs by Western blotting with anti-Src[pY418] antibody. An increase in 
activation levels of c-Src, c-Yes, Lyn, and Fyn was observed in M phase (Fig. 1.2A and 
Supplementary Fig. 1.2B). Furthermore, this increase was blocked by PP2, an SFK inhibitor, in 
M phase (Fig. 1.2B). These results indicate that SFKs, which are endogenously co-expressed in 
HeLa cells, are activated in M phase. 
Intriguingly, electrophoretic mobility of c-Src and c-Yes, but not Lyn, in M phase was 
retarded on SDS–polyacrylamide gels (Fig. 1.2A). However, a mobility shift of Fyn in M phase 
was not certain (Supplementary Fig. 1.2A), because no retarded-mobility form of Fyn was 
immunoprecipitated with anti-Fyn antibody (Supplementary Fig. 1.2B). Next, with 
anti-Src[pY418] antibody we analyzed the activation of each mobility form of c-Src, c-Yes, and 
Lyn in M phase, relative to that of the corresponding SFK in G2 phase. In M phase, normal- and 
retarded-mobility forms of c-Src were activated 1.7 ± 0.3-fold and 1.8 ± 0.3-fold, respectively 
(Fig. 1.2C). In particular, normal- and retarded-mobility forms of c-Yes were greatly activated 
2.6 ± 1.0-fold and 3.9 ± 1.2-fold, respectively (Fig. 1.2C), indicating that activation of the 
retarded-mobility form of c-Yes is higher than that of the normal-mobility form. Similar results 
were obtained in taxol-arrested M-phase cells (data not shown). Furthermore, Lyn53 and Lyn56, 
which did not show any mobility shifts in M phase, were activated 2.1 ± 0.5-fold and 2.4 ± 
0.6-fold, respectively (Fig. 1.2C). These results suggest that normal- and retarded-mobility forms 
of c-Src, c-Yes, and Lyn are all activated in M phase, and that the retarded-mobility form of 
c-Yes is highly activated. 
 
Mobility shifts of c-Src and c-Yes induced by phosphorylation 
Since mitosis-specific phosphorylation of c-Src is known to cause retardation in its 
electrophoretic mobility [13], we compared mobility shifts between c-Src and c-Yes in M phase. 
Normal- and retarded-mobility forms of c-Src and c-Yes were immunoprecipitated from 
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nocodazole-arrested cells and then in vitro treated with calf intestinal alkaline phosphatase 
(CIAP). Treatment with CIAP completely abolished mobility shifts of c-Src and c-Yes (Fig. 1.3). 
The shifts of c-Src and c-Yes were not abolished by CIAP treatment in the presence of Na3VO4, 
a CIAP inhibitor (Fig. 1.3). These results indicate that electrophoretic mobility retardation of 
c-Yes in M phase as well as that of c-Src is caused by their phosphorylation. 
However, it is unlikely that electrophoretic mobility retardation of c-Src in M phase is 
caused by autophosphorylation, because normal- and retarded-mobility forms of c-Src were 
similarly autophosphorylated in M phase (Fig. 1.2A). Furthermore, PP2 treatment of mitotic 
cells decreased autophosphorylation levels of c-Yes without affecting electrophoretic mobility 
shifts of c-Yes (Fig. 1.2B). Thus, these results suggest that mobility shifts of c-Src and c-Yes in 
M phase are induced by mitosis-specific phosphorylation but not autophosphorylation. 
 
Kinetics of mobility shifts of c-Src and c-Yes 
To determine whether mobility shifts of c-Src and c-Yes took place in M phase, we 
examined kinetics of mobility of c-Src, c-Yes, and Lyn during entry into and exit from M phase 
in synchronized HeLa cells. Figure 1.4A and B shows that the appearance of retarded mobility of 
c-Src and c-Yes corresponded to increasing numbers of M-phase cells (see Fig. 1.1A and B) and 
the mobility shifts of c-Src and c-Yes disappeared after exit from M phase (see Fig. 1.1A and C). 
Cyclin B1 expression (Fig. 1.4A and B) and increased solubility of lamin B1 in Triton X-100 
lysis buffer (TX100) (Fig. 1.4C) ensure nuclear lamina fragmentation and nuclear envelope 
breakdown during M phase [44]. Preparation of M-phase cells without nocodazole treatment 
further confirmed that c-Src and c-Yes, but not Lyn, exhibit mobility shifts in M phase (Fig. 
1.4C). In addition to mobility shifts, c-Src, a nonpalmitoylated SFK [4], was fractionated into 
TX100-soluble fraction, whereas c-Yes and Lyn, palmitoylated SFKs [4], were preferentially 
fractionated into TX100-insoluble fraction (Fig. 1.4C), suggesting the effect of SFK 
palmitoylation on TX100 solubility. Taken together, these results indicate that entry into M 
phase plays a role in retarded mobility of c-Src and c-Yes. 
 
Effect of Cdc2 activation on electrophoretic mobility of c-Src, c-Yes, and Lyn 
The kinase activity of Cdc2 increases in M phase and decreases during exit from M phase 
[45]. Cdc2 phosphorylates c-Src in M phase and is responsible for retarded mobility of c-Src [8]. 
To examine whether retarded mobility of c-Yes in M phase was mediated by Cdc2 in vivo, 
M-phase cells were treated with roscovitine, a Cdc2 inhibitor, for the last 30–90 min of 
nocodazole synchronization. Retarded-mobility shifts of c-Src and c-Yes were inhibited by 
roscovitine in a time-dependent manner (Fig. 1.5A). Although roscovitine treatment of M-phase 
cells for more than 2 h completely abolished retarded-mobility shifts of c-Src and c-Yes, 
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prolonged roscovitine treatment caused cytotoxicity such as membrane blebbing (data not 
shown). These results suggest that Cdc2 activity is required for retarded mobility of c-Yes in M 
phase as well as that of c-Src. 
Activation of Cdc2 depends on its association with cyclin B, and the Cdc2/cyclin B 
complex is maintained in an inactive state in interphase by phosphorylation of Cdc2 at Thr14 and 
Tyr15 [27,45]. To assess whether active Cdc2 could induce mobility shifts of c-Src and c-Yes in 
interphase cells, we used the Flag-Cdc2(AF) mutant, in which Thr14 and Tyr15 are replaced 
with alanine and phenylalanine [27], and the non-destructible cyclin B1(R42A)-GFP mutant [26]. 
Asynchronized HeLa cells were transiently co-transfected with Flag-Cdc2(AF) and cyclin 
B1(R42A)-GFP for expression of the active Cdc2/cyclin B complex. In fact, electrophoretic 
mobility of c-Src and c-Yes, but not Lyn, was retarded by expression of both Flag-Cdc2(AF) and 
cyclin B1(R42A)-GFP (Fig. 1.5B, lane 4). Low levels of retarded mobility of c-Src and c-Yes 
may be due to inefficient co-expression with both constructs. Expression of Flag-Cdc2(AF) 
alone minimally retarded c-Src’s mobility (Fig. 1.5B, lane 3), and cyclin B1(R42A)-GFP alone 
had little effect on mobility of c-Src, c-Yes, and Lyn (Fig. 1.5B, lane 2). These results suggest 
that Cdc2 activation is responsible for mobility retardation of c-Src and c-Yes. 
 
Inhibition of mitotic activation of c-Src, c-Yes, and Lyn by roscovitine 
To examine the involvement of Cdc2 in mitotic activation of c-Src, c-Yes, and Lyn, we 
treated M-phase cells with roscovitine for the last 60 min of nocodazole synchronization, and 
then c-Src, c-Yes, and Lyn were immunoprecipitated and analyzed for their activation by 
Western blotting with anti-Src[pY418] antibody. Roscovitine treatment inhibited mobility shifts of 
c-Src and c-Yes in M phase by 47 ± 11% and 31 ± 10%, respectively (Fig. 1.6A and B), with 
concomitant decreases in the kinase activities of c-Src, c-Yes, and Lyn (c-Src, 0.69 ± 0.04-fold; 
c-Yes, 0.73 ± 0.08-fold; Lyn53 and Lyn56, 0.72 ± 0.15- and 0.74 ± 0.16-fold) (Fig. 1.6A and C). 
Taken together, these results suggest that Cdc2 is involved in mitotic activation of c-Src, c-Yes, 
and Lyn. 
 
 
Discussion 
In the present study, we show that electrophoretic mobility of endogenously expressed 
c-Src, c-Yes, and Lyn is differentially involved in their mitotic activation, which is mediated 
through Cdc2 activation. c-Src develops normal- and retarded-mobility forms in M phase, and 
both forms are activated at comparable levels. Although c-Yes, like c-Src, develops two mobility 
forms in M phase, mitotic activation of the retarded-mobility form of c-Yes is higher than that of 
the normal-mobility form. Despite being activated in M phase, Lyn does not develop any 
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mobility-shifted form. Our results lead to a hypothesis that c-Src, c-Yes, and Lyn plays distinct 
but functionally overlapping roles during M phase.  
Previous studies demonstrated that c-Src and Lck exhibit retardation of electrophoretic 
mobility in M phase [13,46,47]. Retarded mobility of mitotic c-Src is caused by Cdc2-mediated 
phosphorylation at Thr37 and Ser75 in the unique domain [8]. Lck is associated with and 
phosphorylated by Cdc2 in M phase [46], and phosphorylation of mitotic Lck at Ser59 in the 
unique domain results in its retarded mobility [47]. Retarded mobility of mitotic c-Yes, which is 
abolished by in vitro phosphatase treatment (Fig. 1.3B), is inhibited by Cdc2 inactivation (Fig. 
1.5A) and forced expression of active Cdc2 in interphase induces mobility retardation of c-Yes 
(Fig. 1.5B). This suggests that mobility retardation of c-Yes is due to its phosphorylation by 
Cdc2. However, Lyn does not exhibit any mobility shifts in M phase (Fig. 1.4 and 
Supplementary Fig. 1.2) and upon forced expression of active Cdc2 in interphase (Fig. 1.5), 
suggesting that Lyn is not phosphorylated by Cdc2 or that phosphorylation of Lyn by Cdc2, if 
any, does not cause its mobility retardation. In fact, c-Yes has five minimal Cdc2 consensus 
phosphorylation sequences (S11PAI, T21PEP, S40PCP, T60PFG, and T69PFG), all of which are 
present in the unique domain, whereas Lyn has only two minimal Cdc2 consensus 
phosphorylation sequences (S196PRI and S228PKP), both of which are found in the SH2 domain. It 
is thus hypothesized that mitotic mobility retardation of SFKs depends on Cdc2-mediated 
phosphorylation of their unique domains. 
Phosphorylation of SFKs has various effects on their kinase activities. For instance, (i) 
phosphorylation of c-Src at Ser12 by protein kinase C does not alter c-Src kinase activity [5], and 
Cdc2-induced phosphorylation of c-Src is reported to unchange c-Src kinase activity [7,8]; (ii) 
phosphorylation of c-Src at Tyr213 by platelet-derived growth factor receptor increases c-Src 
kinase activity [48], and phosphorylation of Hck at Tyr29 by itself increases Hck kinase activity 
[49]; and (iii) phosphorylation of Lck at Ser59, which is the same site for mitotic 
phosphorylation, by MAP kinase decreases Lck kinase activity [9]. Potential sites of c-Src, c-Yes, 
and Lck for Cdc2-mediated phosphorylation are present in their unique domains. Given that the 
sequences of the unique domain of SFKs are highly variable [1,2], the unique domain of SFKs 
may play an important role in their differential mitotic activities. 
Activation of SFKs can be analyzed using in vitro kinase assays with exogenous substrates. 
However, since one cannot easily separate normal- and retarded-mobility forms of SFKs, it is 
difficult to examine activation states of each mobility form of SFKs. To overcome this problem, 
we assayed SFK activation with anti-Src[pY418] antibody. Note that use of anti-Src[pY530] 
antibody in place of anti-Src[pY418] antibody is not suitable for detecting mitotic activation of 
SFKs, because changes in phosphorylation levels at Tyr530 are considerably small in M phase 
[8,50,51]. 
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Intriguingly, activation of the retarded-mobility form of c-Yes is higher than that of the 
normal-mobility form in M phase, whereas c-Src activation is comparable between retarded- and 
normal-mobility forms (Figs. 1.2 and 1.6). A high activation state of the retarded-mobility form 
of c-Yes (Figs. 1.2 and 1.6) can be explained by the possibility that Cdc2-mediated 
phosphorylation of the unique domain in c-Yes strongly induces a conformational change that 
leads to an increase in its catalytic activity. Indeed, we observed that a 135-kDa novel substrate 
of SFKs in M phase is efficiently associated with c-Yes (Supplementary Fig. 1.4 and Fig. 2.1). 
Thus, we provide evidence that electrophoretic mobility of individual SFK members modulated 
by mitosis-specific phosphorylation of the unique domains has different effects on their kinase 
activities during M phase.  
c-Yes, Lyn, and Fyn were preferentially fractionated in TX-100-insoluble fractions, 
whereas c-Src was largely fractionated in TX-100-soluble fractions (Fig. 1.4 and Supplementary 
Fig. 1.2). These results are further substantiated by the finding that c-Yes, Lyn, and Fyn, but 
minimal c-Src, were visualized at the cortical actin cytoskeleton in M phase (Supplementary Fig. 
1.3). Since increasing evidence indicates that SFKs play multiple roles in mitotic events [14–19], 
SFKs may function at different subcellular locations in mitotic cells despite overlapping 
activation of SFKs. Moreover, SFK members can play individual roles in accomplishment of 
diverse physiological events [2]. For instance, c-Yes is preferentially involved in inhibition of 
breast cancer metastasis [52] and degranulation of promyeloid cells [53]. We therefore 
hypothesize that c-Yes plays a preferential, but still overlapping, role in mitotic functions upon 
mitotic activation of individual SFK members. We speculate that SFK members co-expressed in 
a single cell may be involved in diverse steps of the Cdc2-mediated signal transduction pathway. 
Cdc2 consensus phosphorylation sites found in c-Src and c-Yes are conserved among 
human, mouse, and rat. Several epithelial and fibroblastic cell lines showed mitotic mobility 
shifts of c-Src and c-Yes, but not of Lyn (Supplementary Fig. 1.2). Since Cdc2-mediated 
phosphorylation of c-Src and c-Yes may commonly occur during M phase in a wide range of cell 
types, detailed studies will be required for elucidating mitotic roles for overlapping expression of 
SFKs in different cell types. 
Mitotic activation of c-Src, c-Yes, and Lyn is blocked by Cdc2 inactivation (Fig. 1.6), 
suggesting that these SFK members are activated through Cdc2 activity in M phase. However, 
protein-tyrosine phosphatase α (PTPα), whose activity increases in M phase, is also involved in 
c-Src activation through dephosphorylation of the C-terminal tyrosine of c-Src [54]. These 
results suggest that Cdc2 can activate individual SFK members directly or indirectly, possibly 
through activation of PTPα. 
In conclusion, this work shows differential mitotic activation of individual SFK members 
that are endogenously co-expressed in HeLa cells. Electrophoretic mobility shifts and subcellular 
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localizations of SFKs may play a role in SFK functions at M phase. Determination of 
Cdc2-mediated phosphorylation sites in c-Yes and clarification of mitotic roles of c-Yes, c-Src, 
and Lyn are required to dissect their specific and overlapping functions during mitosis in 
epithelial and fibroblastic cells. Furthermore, since multiple SFK members are co-expressed in 
various combinations in a cell type-dependent manner [1,2,55], it is of interest to examine 
mitotic activation of individual SFK members in different cell types such as hematopoietic cells 
that express c-Fgr, Hck, Fyn, Blk, and Lck. 
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Figures 1 
 
 
Fig. 1.1. Cell cycle synchronization. 
(A) HeLa cells were synchronized in each phase of the cell cycle (S → M → G1) using 
aphidicolin and nocodazole, as described under ‘Materials and methods’. At the indicated times, 
DNA contents were analyzed by flow cytometry, and results were shown as histograms of cell 
number (vertical axis) versus DNA content (horizontal axis). Peaks represent 2N (G1 phase) and 
4N (G2/M phase) DNA content. (B) At the indicated times after S-phase release, round-shaped 
(M phase) cells during G2/M synchronization were counted under a phase-contrast microscope. 
Data represent means ± SD from three independent experiments. (C) (Asyn) Asynchronized cells, 
(Noc 16 h) cells released from S-phase arrest and treated with nocodazole for further 16 h, and (3 
h after Noc release) cells released from nocodazole arrest and cultured for further 3 h were 
stained for cyclin B1 (green, CycB1) and DNA (red). Cyclin B1 was expressed in cells treated 
with Noc 16 h. An arrow and arrowheads indicate a spreading cell (G2 phase) and round-shaped 
cells (M phase), respectively. The appearance of a small nucleus or multi-nuclei (C) in cells that 
re-enter into G1 phase may be due to abnormal mitotic exit after nocodazole arrest. Bars, 10 µm. 
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Fig. 1.2. Mitotic activation of c-Src, c-Yes, and Lyn.  
(A) HeLa cells were synchronized in G2/M phase upon treatment with nocodazole for 13–14 h 
after S-phase release, and then round-shaped (M phase) cells were separated from spreading (G2 
phase) cells. (B) HeLa cells were treated with 5 µM PP2 or DMSO (solvent control) for the last 
1 h of synchronization in G2/M phase with nocodazole for 16 h, and then round-shaped (M 
phase) cells were collected. c-Src, c-Yes, or Lyn was immunoprecipitated from cells prepared as 
described above. Immunoprecipitates were analyzed by SDS–PAGE and Western blotting. 
Double primes (″) indicate electrophoretically mobility-shifted forms. Lyn53 (Lyn at 53 kDa) 
and Lyn56 (Lyn at 56 kDa), two alternative spliced isoforms of Lyn. (C) Relative activity of 
each SFK band was quantitated as follows: the signal intensity detected with anti-Src[pY418] 
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antibody was normalized to the amount of the corresponding band, and values were compared 
with those of normal-mobility forms of SFKs in G2 phase. Results are expressed as means ± SD 
from more than three independent experiments (c-Src, n = 3; c-Yes, n = 4; Lyn, n = 4). Shaded 
bars, normal-mobility forms in G2 phase; filled bars, normal-mobility forms in M phase; open 
bars, retarded-mobility forms in M phase. Asterisks indicate significant differences (*p < 0.05, 
** p < 0.01) calculated by Student′s t-test (NS, not significant).  
 
 
Fig. 1.3. Electrophoretic mobility shifts of c-Src and c-Yes in M phase induced by 
phosphorylation. 
c-Src (A) or c-Yes (B) was immunoprecipitated from HeLa cells that were synchronized in G2/M 
phase. Immunoprecipitates were untreated (–) or treated (+) with alkaline phosphatase (CIAP) 
for 2 h at 37°C in alkaline buffer in the presence (+) or absence (–) of 3 mM Na3VO4, a CIAP 
inhibitor. Samples were analyzed by SDS–PAGE and Western blotting. Double primes (″) 
indicate retarded-mobility forms. 
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Fig. 1.4. Kinetic comparison of electrophoretic mobility among c-Src, c-Yes, and Lyn. 
Whole cell lysates were prepared from cells released from S-phase arrest (S-arrest) in the 
presence of nocodazole (A) or cells released from nocodazole arrest (Noc arrest) (B). The 
indicated times (hour) show incubation periods after washing free of aphidicolin (A) and 
nocodazole (B). (C) Triton X-100 (TX100)-soluble and -insoluble fractions were prepared from 
G2- and M-phase cells isolated using nocodazole [(+)Nocodazole] as described in Fig. 1.2A or 
from M-phase cells prepared without nocodazole [(–)Nocodazole] as described under ‘Materials 
and methods’. Lysates of asynchronized (Asyn) cells were used as controls (see Fig. 1.1A). 
Samples were analyzed by SDS–PAGE and Western blotting. Double primes (″) indicate 
mobility-shifted forms. Lyn53 and Lyn56, two alternative spliced isoforms of Lyn. 
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Fig. 1.5. Electrophoretic mobility shifts of c-Src and c-Yes induced by Cdc2 activation.  
(A) HeLa cells were treated with 50 µM roscovitine for the indicated times (min) or with DMSO 
(solvent control) for the last 90 min of G2/M synchronization, and round-shaped (M phase) cells 
were collected. (B) Cells were untransfected (lane 1) or transiently transfected with cyclin 
B1(R42A)-GFP (lane 2), Flag-Cdc2(AF) (lane 3), or cyclin B1(R42A)-GFP plus Flag-Cdc2(AF) 
(lane 4). Whole cell lysates were analyzed by SDS–PAGE and Western blotting. As controls, 
asynchronized (Asyn; A, right lane) and G2/M-synchronized (B, lane 5) cells were used. 
Although two bands of Flag-Cdc2(AF) were detected with anti-FLAG antibody, the lower band 
corresponds to the expected molecular size (B). Double primes (″) indicate retarded-mobility 
forms. CycB1(R42A), cyclin B1(R42A)-GFP; Lyn53 and Lyn56, two alternative spliced 
isoforms of Lyn. 
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Fig. 1.6. Inactivation of mitotic c-Src, c-Yes, and Lyn induced by Cdc2 inhibition.  
(A) HeLa cells were treated with 50 µM roscovitine or DMSO (solvent control) for the last 1 h 
of G2/M synchronization, and round-shaped (M phase) cells were collected. c-Src, c-Yes, or Lyn 
was immunoprecipitated from DMSO- or roscovitine-treated M-phase cells, and 
immunoprecipitates were analyzed by SDS–PAGE and Western blotting. Double primes (″) 
indicate retarded-mobility forms. Lyn53 and Lyn56, two alternative spliced isoforms of Lyn. (B) 
Levels of mobility shifts of c-Src and c-Yes were calculated from the amount of 
retarded-mobility form of c-Src or c-Yes per total amount of the corresponding SFK. (C) 
Activities of SFKs were calculated as the signal intensity detected with anti-Src[pY418] antibody 
per the amount of the corresponding SFK. Results obtained from roscovitine-treated M-phase 
cells (means ± SD from three independent experiments) were expressed relative to values in 
DMSO-treated M-phase cells (B, C). Asterisks indicate significant differences (+p < 0.1, * p < 
0.05, *** p < 0.005) calculated by Student′s t-test (NS, not significant). Open bars, 
DMSO-treated M-phase cells; filled bars, roscovitine-treated M-phase cells.  
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Supplementary Figures 1 
 
Supplementary Fig. 1.1. Overlapping expression of c-Src, c-Yes, Lyn, and Fyn in epithelial 
and fibroblastic cell lines. 
Epithelial cell lines are HeLa, HT-H, HEK293, and A431; fibroblastic cell lines are COS-1 and 
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NIH3T3. HeLa (A), COS-1 (B), HT-H (C), HEK293 (D), A431 (E), and NIH3T3 (F) cells were 
lysed in Triton X-100 lysis buffer (TX100; A, C) or SDS–PAGE sample buffer (B, D, E, and 
F-a). Lyn was immunoprecipitated from Empigen-solubilized lysates of NIH3T3 cells (F-b). 
Lysates (A–E, F-a) and Lyn immunoprecipitate (F-b) were analyzed by SDS–PAGE and 
Western blotting. c-Src, c-Yes, and Fyn were detected at 60, 62, and 59 kDa, respectively. Two 
alternative spliced isoforms of Lyn are expressed at 53 kDa (Lyn53) and 56 kDa (Lyn56). 
Molecular mass markers are shown in kDa. 
 
 
Supplementary Fig. 1.2. Electrophoretic mobility of SFKs in mitotic HeLa, COS-1, and 
HT-H cells.  
(A, B) Round-shaped (M phase) and spreading (G2 phase) HeLa cells were collected in the 
presence of nocodazole, as described in Fig. 1.2A. (C, D) HT-H or COS-1 cells were treated with 
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nocodazole for 16 h, and then round-shaped (M phase) cells were collected. M phase, G2 phase, 
and asynchronized (Asyn) cells were fractionated into TX100-soluble and -insoluble fractions (A, 
C, D). Samples were analyzed by SDS–PAGE and Western blotting. Double primes (″) indicate 
retarded-mobility forms. Lyn53 and Lyn56, two alternative spliced isoforms of Lyn. 
Electrophoretic mobility of c-Src and c-Yes, but not Lyn, was retarded in M-phase cells (A, C, 
D). Fyn was electrophoretically retarded in mitotic HeLa (A) but not HT-H (C) cells. Fyn was 
immunoprecipitated from G2-phase and M-phase HeLa cells (B), as described in Fig. 1.2A, and 
analyzed with anti-Fyn and anti-Src[pY418] antibodies. Fyn was activated in M phase, when 
relative activity of Fyn was quantitated (B, bottom panel), as described in Fig. 1.2C. Note that 
the retarded-mobility form of Fyn was not immunoprecipitated. Results shown are representative 
of two independent experiments.  
 
 
Supplementary Fig. 1.3. Subcellular localization of SFKs in mitotic HeLa cells. 
HeLa cells were transfected with c-Src (A), c-Yes (B), Lyn (C), or Fyn (D). Cells were stained 
with anti-Src(327), anti-Yes(1), anti-Lyn(H-6), or anti-Fyn (3) antibody for expressed proteins 
(green), with rhodamine-phalloidin for F-actin (red), and with DAPI for DNA (data not shown). 
In metaphase cells with aligned chromosomes, c-Src was largely localized in the cytosol and/or 
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intracellular organelles, whereas c-Yes, Lyn, and Fyn were co-localized with the cortical actin 
cytoskeleton. Bars, 10 µm. 
 
 
Supplementary Fig. 1.4. Association of SFKs with tyrosine-phosphorylated proteins in M 
phase.  
(A) c-Src, c-Yes, or Lyn was immunoprecipitated from HeLa cells asynchronized (Asyn) or 
arrested with nocodazole (Noc). (B) c-Yes was immunoprecipitated from asynchronized (Asyn) 
or M-phase (M phase) cells that were isolated from nocodazole-arrested cells treated with 5 µM 
PP2 or DMSO as described in Fig. 1.2B. Immunoprecipitates were analyzed by SDS–PAGE and 
Western blotting. Tyrosine-phosphorylated proteins at 135 kDa (pp135), 115 kDa (pp115), 90 
kDa (pp90), 85 kDa (pp85), 70 kDa (pp70), and 68 kDa (pp68) were detected with anti-pTyr 
antibody. Arrowheads indicate heavy chains of antibodies used for immunoprecipitation of SFKs. 
Double primes (″) indicate retarded-mobility forms. Lyn53 and Lyn56, two alternative spliced 
isoforms of Lyn.
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Part II 
 
Separation of a disulfide-linked phosphoprotein by diagonal 
SDS–PAGE with optimized gel crosslinking 
 
 
     Identification of proteins is achieved with high sensitivity by mass spectrometry [56]. 
Many proteins, including the T-cell receptor complex and the insulin receptor [57,58], contain 
intermolecular disulfide bonds that play an important role in formation of a functional signaling 
protein complex. Protein components of an intermolecular disulfide-linked complex can be 
selectively separated and purified by diagonal two-dimensional (2-D) SDS–PAGE. The first 
dimension is run under non-reducing conditions, and the second dimension is under reducing 
conditions [59]. If a protein of interest co-migrates with large amounts of other proteins on a 
diagonal 2-D gel, it cannot be identified unambiguously. The chance to identify proteins 
correctly depends on their purity [60]. Here, we report an approach to separate a disulfide-linked 
phosphoprotein from contaminant proteins that co-migrate on a diagonal 2-D gel. The separation 
can be achieved by SDS–PAGE on gels with different degrees of gel crosslinking, that is, 
different ratios of N, N′-methylenebisacrylamide (bisacrylamide)/acrylamide. 
     By diagonal 2-D SDS–PAGE analysis of mitotic HeLa cell lysates, two spots of a 
tyrosine-phosphorylated protein at 135 kDa (pp135) were found below the diagonal line (Fig. 
2.1A, right, long arrows). This indicates that pp135 forms an intermolecular disulfide-linked 
complex in mitotic HeLa cells. Phosphorylation of pp135 was specifically observed at M phase 
and inhibited by PP2, an inhibitor of SFKs (Fig. 2.1A, left), suggesting that pp135 is a mitotic 
substrate of SFKs. pp135 was efficiently associated with c-Yes (Supplemental Fig. 1.4).  
     To identify pp135 by mass spectrometry, we tried to purify a disulfide-linked species of 
pp135 using diagonal 2-D SDS–PAGE. pp135 was resistant to solubilization in Chaps lysis 
buffer (1% [w/v] Chaps, 50 mM Hepes–KOH, pH 7.2, 80 mM KCl, 2 mM EGTA, 0.2 mM 
spermine, 0.5 mM spermidine, 50 µg/ml aprotinin, 100 µM leupeptin, 25 µM pepstatin A, and 2 
mM phenylmethylsulfonyl fluoride) supplemented with tyrosine-phosphatase inhibitors, 10 mM 
Na3VO4 [38,41] and 5 µM ZnCl2 [61] (Fig. 2.1A). To eliminate irrelevant cytosolic and 
membrane-bound proteins, Chaps-insoluble fractions were obtained from 2.5 x 107 mitotic cells, 
dissolved in non-reducing SDS–PAGE sample buffer and resolved by SDS–PAGE as the first 
dimension. A gel area containing disulfide-linked pp135 at around 200 to 300 kDa was cut out 
from the first dimensional gel (Fig. 2.1B, upper). The gel piece was incubated in SDS sample 
buffer containing 5% (v/v) β-mercaptoethanol at 50°C for 50 min in changes of the same buffer 
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every 10 minutes to reduce disulfide linkages of proteins. To confirm the presence of pp135 in 
the gel piece, a small fraction of the gel piece was subjected to SDS–PAGE under reducing 
conditions as the second dimension, followed by Western blotting with anti-phosphotyrosine 
(pTyr) antibody (4G10; Upstate Biotechnology, Inc.) (Fig. 2.1B, right). Proteins in the remaining 
gel piece were eluted and resolved by SDS–PAGE as the second dimension, transferred to a 
PVDF membrane (Problot, Applied Biosystems), and stained with colloidal gold as described 
previously [41]. Many protein bands were observed between 97 and 200 kDa (Fig. 2.1B, left), 
most of which were below the diagonal line (data not shown). Intriguingly, pp135 was found to 
correspond to two protein bands. Each of the two protein bands was cut out, reduced, 
S-carboxymethylated, and digested in situ with Achromobacter protease I (Lys-C) in digestion 
buffer (20 mM Tris–HCl, pH9.0, 70% [v/v] acetonitrile, and 0.0005% [v/v] Triton X-45) [41,62]. 
Lys-C digests were purified using Zip-TipHPL pipette tips (Millipore) under high acetonitrile 
concentrations. The digestion method enabled high yields of Lys-C fragments. Molecular mass 
analyses of Lys-C fragments were performed by matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI–TOF MS) using a PerSeptive Biosystems Voyager 
DE/RP mass spectrometer, and then peptide mass fingerprinting was performed. The upper band 
was identified as human chromosome-associated protein E (hCAP-E), a component of the 
condensin complex that is required for mitotic chromosome condensation [63]. The masses of 
the 13 Lys-C fragments obtained from the upper band were all matched to the theoretical peptide 
masses of hCAP-E. The lower band could not be identified, probably owing to an insufficient 
amount of the protein. In addition, the non-phosphorylated protein at 120 kDa was identified as 
hCAP-G (data not shown), another component of the condensin complex [64], suggesting that 
some condensin components may form disulfide linkages. 
     To examine whether hCAP-E was tyrosine-phosphorylated in M phase, Chaps-insoluble 
fractions of mitotic cells were analyzed by diagonal 2-D SDS–PAGE and Western blotting with 
anti-pTyr and anti-hCAP-E [63] antibodies. Fig. 2.2A shows that the spots of pp135 (arrows) 
overlapped only partly with hCAP-E. These results indicate that pp135 was misidentified as 
hCAP-E because of co-migration of pp135 with hCAP-E. It is likely that the expression level of 
pp135 is considerably lower than that of hCAP-E. 
     To obtain Lys-C fragments of pp135 in MS analysis, it is necessary to separate pp135 
from hCAP-E on a diagonal 2-D gel and to purify sufficient amounts of pp135. Electrophoretic 
mobility of proteins is often changeable depending on the degree of gel crosslinking [65]. Since 
varying the ratio of bisacrylamide to acrylamide can change the degree of gel crosslinking [66], 
we examined electrophoretic mobility of pp135 and hCAP-E on 5.0%T SDS–polyacrylamide 
gels (%T [w/v], percentage of total acrylamide [acrylamide + bisacrylamide]) with various %C 
bisacrylamide (%C [w/w], percentage of bisacrylamide/total acrylamide). Although pp135 
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co-migrated with hCAP-E on SDS–polyacrylamide gels with 1.9 and 2.7%C, pp135 exhibited 
higher electrophoretic mobility than hCAP-E on gels with 3.5 to 9.0%C (Fig. 2.2B). Note that 
2.7%C was used in this study for diagonal 2-D SDS–PAGE. Thus, pp135 can be separated from 
hCAP-E and purified by diagonal 2-D SDS–PAGE, in which the second dimension is run on a 
gel with 3.5 to 9.0%C.  
     In this report, using different %C SDS–polyacrylamide gels we showed that pp135 is 
clearly separated from hCAP-E, which co-migrates with pp135 on a standard diagonal 2-D gel. 
Changes in electrophoretic mobility of pp135 on high %C gels ensure complete separation of 
pp135 from hCAP-E. Interestingly, electrophoretic mobility of phosphoproteins, including 
phosphorylated mitogen-activated protein kinase (MAPK) and protein kinase C, varies 
considerably from that of their non-phosphorylated forms, when %C of SDS–polyacrylamide 
gels is changed [67,68]. Therefore, manipulation of gel crosslinking in a diagonal 2-D gel 
situation can increase the chance to purify and identify a disulfide-linked signaling 
phosphoprotein appearing at M phase with a low expression level. The method reported here is 
applicable to purification of phosphoproteins that are bridged by disulfide bonds. 
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Figures 2  
 
Fig. 2.1. Purification of a tyrosine-phosphorylated protein by diagonal 2-D SDS–PAGE. 
(A) HeLa cells (Japanese Collection of Research Bioresources) were synchronized in M phase 
with 0.1 µg/mL nocodazole for 16 h after S-phase pre-synchronization with 1 µg/mL aphidicolin 
for 24 h. Mitotic cells were treated with PP2 at the indicated concentrations for the last 1 h of 
synchronization (left). Asynchronized cells (Asyn) were used as a control. Whole cell lysates 
(left) and Chaps-insoluble fractions (middle and right) of mitotic cells were resolved by 
SDS–PAGE (4 x 104 cells/lane, left and middle) or diagonal 2-D SDS–PAGE (4 x 105 cells, 
right). Diagonal 2-D SDS–PAGE was performed as follows: the first dimension was run under 
non-reducing conditions (NR) in a glass capillary tube (Figs. 2.1A and 2.2A) or on a slab gel 
(Fig. 2.1B), and the second dimension was run on a slab gel under reducing conditions (R). 
Western blotting with anti-phosphotyrosine (pTyr) antibody was performed as described [17]. 
Phosphorylation of pp135, 85, 63, and 56 was specifically detected at M phase and inhibited by 
PP2. Long and short arrows indicate pp135 off and on the diagonal line, respectively (right).  
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(B) Disulfide-linked species of pp135 were purified from Chaps-insoluble fractions of mitotic 
cells (2.5 x 107 cells) by diagonal 2-D SDS–PAGE. A gel area in the first dimensional 
SDS–PAGE (hatched square) was recovered for the second dimensional SDS–PAGE. Proteins 
were transferred to a PVDF membrane, and stained with Colloidal Gold Total Protein Stain Kit 
(Bio-Rad) (Protein staining) or analyzed by Western blotting for pTyr. Gel concentrations were 
10%T (2.7%C) (A, left) and 5.0%T (2.7%C) (A, middle and right, and B). Molecular size 
markers (in kDa) are indicated. 
 
 
Fig. 2.2. Separation of pp135 from hCAP-E by SDS–PAGE on various %C crosslinking 
gels.  
Chaps-insoluble fractions of mitotic cells were resolved by diagonal 2-D SDS–PAGE using 
5.0%T gels with 2.7%C (4 x 105 cells, A) and one-dimensional SDS–PAGE using 5.0%T gels 
with the indicated %C (4 x 104 cells/lane, B), and analyzed by Western blotting for pTyr and 
subsequently for hCAP-E after reproving. Schematic diagram of a blot with anti-pTyr (enclosed 
areas) and anti-hCAP-E (gray areas) antibodies is shown, and long and short arrows indicate 
pp135 off and on the diagonal line, respectively (A). Molecular size markers (in kDa) are 
indicated on the left. Thick broken line: pp135; intermediate broken line: hCAP-E; thin broken 
line: tyrosine-phosphorylated protein at approximately 150 kDa (*); NR: non-reducing 
conditions (first dimension); R: reducing conditions (second dimension).
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Part III 
 
Role of Src-family kinases in actin cap formation at  
the dorsal cell surface 
 
Abstract 
Protein-tyrosine phosphorylation is regulated by protein-tyrosine kinases and protein-tyrosine 
phosphatases (PTPs). Src-family tyrosine kinases (SFKs) participate in the regulation of the actin 
cytoskeleton. Actin filaments can be accumulated in a “cap” at the dorsal cell surface, which is 
called the actin cap. Here, we show that SFKs play an important role in actin cap formation. 
HeLa cells normally form the actin cap. Immunofluorescence with anti-phosphotyrosine 
antibody reveals that the actin cap is one of the major sites of tyrosine phosphorylation. 
Formation of the actin cap is inhibited by SFK inhibitors (PP2 or SU6656). Csk-knockout cells 
form the actin cap in the presence of Na3VO4, an inhibitor of PTPs, and the actin cap formation is 
suppressed by SFK inactivation with re-introduction of Csk. SYF cells lacking expression of 
ubiquitous SFK members minimally exhibit the actin cap even in the presence of Na3VO4, and 
transfection of the cells with Lyn, an SFK member, restores actin cap formation in the presence 
of Na3VO4. Additionally, the actin cap in HeLa cells is disrupted by dominant-negative Lyn 
constructs in a manner dependent on the SH3 domain. These results suggest that actin cap 
formation is induced by an increase in SFK-mediated tyrosine phosphorylation.  
 
 
Introduction 
Protein-tyrosine phosphorylation is regulated by protein-tyrosine kinases (PTKs) and 
protein-tyrosine phosphatases (PTPs) [69–71]. A wide variety of stimuli, including growth 
factors, cytokines, hormones, extracellular matrix components, and cell adhesion molecules, 
transmit signals via pathways involving tyrosine phosphorylation of specific cellular proteins. 
These signal transduction pathways dictate whether a cell will grow and divide, change shape, 
move, differentiate, or die [69–71]. 
Src-family tyrosine kinases (SFKs) belong to a group of non-receptor-type tyrosine kinases. 
SFKs are involved in a wide range of signaling events, resulting in cell proliferation, 
differentiation, migration, and cell shape changes [1,2]. SFKs consist of proto-oncogene products 
and structurally related proteins and include at least eight highly homologous proteins: c-Src, 
c-Yes, Lyn, Fyn, Lck, Hck, Blk, and c-Fgr [1,2]. c-Src, c-Yes, Fyn, and Lyn are widely 
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expressed in a variety of cell types, whereas Blk, c-Fgr, Hck, and Lck are found primarily in 
hematopoietic cells [1,2,72]. Multiple combinations in expression of each SFK member in a 
single cell are implicated to serve specific and overlapping functions [1,2,73–77].  
SFKs are composed of: (i) a Src homology (SH) 4 domain, which contains lipid 
modification sites, (ii) a poorly conserved “unique” domain, (iii) an SH3 domain, which can bind 
to specific proline-rich sequences, (iv) an SH2 domain, which can bind to specific sites of 
tyrosine phosphorylation, (v) an SH1 tyrosine kinase catalytic domain, and (vi) a negative 
regulatory tail for autoinhibition of kinase activity [1,2]. The kinase activity of SFKs is repressed 
through creating a distinctive “closed conformation” due to the intramolecular bindings of the 
SH2 domain to the tyrosine-phosphorylated tail catalyzed by the Csk-family and of the SH3 
domain to the SH2-kinase linker. SFKs can interact with a large number of upstream regulators 
and downstream substrates through protein–protein interaction [1,2]. 
Activation of SFKs leads to rapid and profound changes in the cytoskeleton. Indeed, a 
number of SFK substrates are shown to regulate the actin cytoskeleton [1,2,78,79]. The actin 
cytoskeleton maintains cellular shape and plays a pivotal role in cell motility, adhesion, 
endocytosis, and cytokinesis [80–83]. A cell forms a number of discrete types of actin-based 
structures designed to fulfill specialized roles: for example, actin stress fibers, lamellipodia and 
ruffles, and filopodia [80,84,85]. Actin filaments can be accumulated in a “cap” at the dorsal cell 
surface, which is called the actin cap [86]. 
In this study, we examined the involvement of SFKs in formation of the actin cap, which is 
one of the major subcellular sites of tyrosine phosphorylation. We show that SFKs play an 
important role in actin cap formation in HeLa cells using SFK inhibitors and dominant-negative 
Lyn constructs. The requirement of SFKs for actin cap formation is further substantiated by an 
inducible expression system for Csk in Csk-knockout cells and transfection experiments with 
Lyn into SYF cells lacking expression of ubiquitous SFK members. Our results indicate that an 
increase in SFK-mediated tyrosine phosphorylation induces formation of the actin cap. 
 
 
Materials and methods  
Plasmids 
cDNAs encoding human c-Src (provided by D.J. Fujita [28]) and human Lyn (1–512; with 
1 designating the initiator methionine) (provided by T. Yamamoto [30]) were subcloned into the 
pcDNA4/TO vector (Invitrogen) as described [32,42]. Lyn∆K-HA (1–298), subcloned into the 
pMKITneo vector (provided by K. Maruyama), was constructed as described [32]. 
Lyn∆K∆SH2-HA (1–164 and 245–298) was generated from Lyn∆K-HA by HindIII and SmaI 
digestion and blunting. Lyn∆K∆SH3-HA (1–61 and 118–298) was generated as follows. The 
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DNA fragment corresponding to the amino acid sequence 1–61 of Lyn was amplified by PCR 
using the sense primer 5′-AAACACGCGTCGAGCGGGAAATATGGGATGT-3′ and the 
antisense primer 5′-AGAATGGCCACCTCTGGATCTTTAGTTTGAAACC-3′, and the 
amplified fragment was ligated with the fragment (118–298) of Lyn∆K-HA. Lyn∆K∆SH2-HA 
and Lyn∆K∆SH3-HA were subcloned into pMKITneo. Lyn118-GFP (1–118) was generated by 
fusion with EGFP obtained from the pEGFP-C1 vector (Clontech Laboratories, Inc.) and 
subcloned into pcDNA4/TO. The Trp→Ala mutation at position 99 [Lyn118(W99A)-GFP] was 
generated by site-directed mutagenesis using the sense primer 
5′-GGGACTTTGCTTTCCAAGCTTCTCCATGCTCCTCCAGG-3′ and the antisense primer 
5′-CCTGGAGGAGCATGGAGAAGCTTGGAAAGCAAAGTCCC-3′. Rat Csk cDNA was 
provided by M. Okada and S. Nada [87]. Csk-HA (1–440) generated previously [32] was 
subcloned into pcDNA4/TO. The BOSH2BGFP-N1 vector encoding GFP-tagged histone H2B 
was provided by H. Saya [88,89]. mCherry-β-actin was constructed in the pEGFP-β-actin vector 
(provided by H. Bito [90]) by substitution of EGFP for mCherry obtained from the 
pRSET-B-mCherry vector (provided by R.Y. Tsien [91]) using NheI and Bsp1407I. Western 
blotting analyses confirmed protein expression with predicted molecular sizes (data not shown). 
?  
Cells and cell culture 
HeLa (Japanese Collection of Research Bioresources), MCF-7 (provided by H. Saya), 
A431 (provided by M.N. Fukuda), COS-1, NIH3T3 (provided by K. Igarashi), and Csk-knockout 
D5, and c-Src/c-Yes/Fyn-knockout SYF cells (provided by M. Okada and S. Nada) [77,92] were 
cultured in Iscove’s modified Dulbecco’s medium containing 5% fetal bovine serum (FBS). 
Transient transfection was performed using TransIT transfection reagent (Mirus) or 
LipofectAMINETM 2000 reagent (Invitrogen) [42]. The kinase activity of SFKs was specifically 
inhibited by PP2 (Calbiochem) [23] or SU6656 (Calbiochem) [93]. Na3VO4 was used to inhibit 
PTPs [94].   
 
Csk-inducible D5/Csk32-5 cell line 
The pCAG-TR (the tetracycline repressor) vector was constructed by subcloning TR 
obtained from the pcDNA6/TR vector (Invitrogen) into the pCAG vector (provided by J. 
Miyazaki [95]), as described for generation of the HeLa #3-2 clone [22]. A D5 cell clone 
co-transfected with pCAG-TR and a plasmid containing the hygromycin-resistance gene was 
selected in medium containing 5% FBS and 300 µg/ml hygromycin B (Wako Pure Chemicals, 
Osaka). TR expression in clone #51-13 was detected by Western blotting with anti-TR antibody 
(MoBiTec) (data not shown). The Csk-inducible D5/Csk32-5 cell line was generated from clone 
#51-13 by transfection with pcDNA4/TO (Invitrogen) expressing Csk-HA and selection in 
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medium containing 5% FBS and 400 µg/ml Zeocin (Invitrogen). Doxycycline (Dox) was used at 
1 µg/ml for 48 h to induce Csk-HA. 
 
Antibodies 
The following antibodies were used: c-Src (clone 327; Oncogene Research), Lyn (H-6 and 
Lyn44; Santa Cruz Biotechnology), phosphotyrosine (pTyr, 4G10; Upstate Biotechnology, Inc), 
HA epitope (F-7 and Y-11; Santa Cruz Biotechnology), Csk (clone 52; BD Transduction 
Laboratories), α-tubulin (MCA78G; Serotec), and Src[pY418] (BioSource International or Cell 
Signaling Technology). FITC- and horseradish peroxidase-F(ab’)2 secondary antibodies were 
purchased from BioSource and Amersham Biosciences, respectively. 
  
Immunofluorescence 
Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 
min at room temperature, permeabilized in PBS containing 0.1% saponin and 3% bovine serum 
albumin for 1 h, and stained with appropriate antibodies as described [17,33,34,37]. F-actin was 
stained with rhodamine-phalloidin as described [36,72]. Stained cells were viewed under a 
Fluoview FV500 confocal laser scanning microscope (Olympus, Tokyo). Live-cell imaging was 
performed as described [22,32,42]. 
 
Western blotting 
Cells were directly lysed in SDS–PAGE sample buffer. Lysates were analyzed by 
SDS–PAGE and Western blotting using the enhanced chemiluminescence (ECL) detection 
system (GE Healthcare) as described [35,38–41]. Images of chemiluminescence were obtained 
using an Image Analyzer LAS-1000plus (Fujifilm, Tokyo). Sequential reprobing of membranes 
with appropriate antibodies was performed as described [17,96]. Intensity of chemiluminescence 
was measured using the ImageJ software (National Institutes of Health). 
 
 
Results 
Visualization of tyrosine phosphorylation at the actin cap 
Tyrosine phosphorylation events often occur at specific subcellular sites, including focal 
adhesions, filopodia tips, and podosomes [80,85,97]. To dissect tyrosine phosphorylation sites in 
HeLa cells, growing cells were visualized with anti-phosphotyrosine (pTyr) antibody for tyrosine 
phosphorylation and rhodamine-phalloidin for F-actin and analyzed by confocal microscopy. We 
found conspicuous staining for tyrosine phosphorylation at the bottom and top of cells. Tyrosine 
phosphorylation at the bottom of cells was mainly detected at focal adhesions that were located 
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at the ends of actin stress fibers (Fig. 3.1A). In contrast, tyrosine phosphorylation at the top of 
cells was detected at a meshwork of actin filaments (Fig. 3.1A). Tyrosine phosphorylation at the 
actin meshwork was enhanced by treatment with 0.1 mM Na3VO4, an inhibitor of PTPs, for 5min 
(Fig. 3.1B), suggesting that tyrosine phosphorylation at the actin meshwork is regulated by PTKs 
and PTPs. Serial sections of cells that were stained for F-actin showed that a meshwork of actin 
filaments is restricted in a “cap” at the top of cells (Fig. 3.1C) and that the actin cap is positioned 
nearly above the nucleus (Fig. 3.1D). The actin cap was detected in cells that expressed cyclin 
B1 at high (G2 phase) and low (G1 and S phases) concentrations (Supplementary Fig. 3.1A), 
indicating that the actin cap is organized throughout the cell cycle. Live-cell imaging showed 
that the morphology of the actin cap drastically changed during mitosis (Supplementary Fig. 
3.1B). The actin cap was formed independently of cell confluency and cell–cell contact (data not 
shown). Nomarski microscopy showed that dorsal cell membranes protruded along actin 
filaments in the actin cap (Supplementary Fig. 3.2), suggesting that the actin cap may be a class 
of membrane ruffles and/or microvilli-like structures. In addition, the actin cap was seen in 
MCF-7 and A431 cells, but these cells exhibited the actin cap at low levels (data not shown). 
Taken together, these results suggest that the actin cap as well as focal adhesions is one of the 
major sites of tyrosine phosphorylation. 
 
 
Disruption of the actin cap by SFK inhibitors 
To examine whether SFKs were involved in formation of the actin cap, we treated HeLa 
cells with 10 µM PP2, an SFK-specific inhibitor, for 1 h. Intriguingly, PP2 treatment disrupted 
the actin cap, accompanying decreased tyrosine phosphorylation at the top of cells (Fig. 3.2A). 
Fig. 3.2C shows that PP2 treatment decreased numbers of cells exhibiting the actin cap in a 
concentration-dependent manner (control, 94 ± 2%; 5 µM, 74 ± 5%; 10 µM, 61 ± 7%; 20 µM, 53 
± 2%). Treatment of cells with 5 µM SU6656, another SFK-specific inhibitor, further confirmed 
disruption of the actin cap by inactivation of SFKs (Fig. 3.2D). Unlike the actin cap, actin stress 
fibers were not disrupted by SFK inhibitors (Fig. 3.2B). These results suggest that SFK activity 
is required for actin cap formation. 
 
Inhibition of actin cap formation by inducible Csk expression 
Csk phosphorylates the C-terminal inhibitory tyrosine of SFKs, resulting in inactivation of 
SFKs [87]. To further examine the requirement of SFK activity for actin cap formation, we 
established a Csk-inducible cell line from Csk-knockout D5 cells [92]. We first quantitated the 
actin cap in parental D5 cells and found that small proportions of cells exhibited the actin cap (11 
± 4%) (Fig. 3.3B and C). Given that D5 cells showed various SFK substrates whose tyrosine 
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phosphorylation was not induced [92], we hypothesized that low levels of actin cap formation in 
D5 cells are due to insufficient SFK-mediated tyrosine phosphorylation. To test this hypothesis, 
tyrosine phosphorylation in D5 cells was enhanced by treatment with 0.5 mM Na3VO4 for 1 h 
(Fig. 3.3A and B). Fig. 3.3B and C shows that Na3VO4 treatment increased numbers of cells 
exhibiting the actin cap (62 ± 6%). Similarly, actin cap formation was seen in COS-1 cells upon 
Na3VO4 treatment (data not shown). Inactivation of SFKs by PP2 prevented the effect of Na3VO4 
on tyrosine phosphorylation and actin cap formation (Fig. 3.3A, B, and D). These results suggest 
that actin cap formation in D5 cells is induced by an increase in SFK-mediated tyrosine 
phosphorylation. 
Upon incubation of D5/Csk32-5 cells with 1 µg/ml doxycycline (Dox), a tetracycline 
analog, cells inducibly expressed HA-tagged Csk (Csk-HA) at similar levels to endogenous Csk 
in NIH3T3 cells, whereas D5/Csk32-5 cells did not show any expression of Csk in the absence 
of Dox (Fig. 3.4A). Induction of Csk-HA decreased SFK activity by approximately 30–40% (Fig. 
3.4B). Treatment of D5/Csk32-5 cells with 0.5 mM Na3VO4 for 1 h increased numbers of cells 
exhibiting the actin cap in the absence of Dox (8 ± 2% → 49 ± 14%) (Fig. 3.4C). Induction of 
Csk-HA by Dox inhibited Na3VO4-induced formation of the actin cap by 29 ± 4% (Fig. 3.4D and 
E). Actin stress fibers were not affected by induction of Csk-HA (Fig. 3.4D). These results 
suggest that actin cap formation is regulated by SFK activity. 
 
Actin cap formation mediated by Lyn 
Using mouse embryonic fibroblast SYF cells, which are genetically deficient in expression 
of c-Src, c-Yes, and Fyn and do not express Lyn at a detectable level [77], we further 
substantiated the requirement of SFKs for actin cap formation. SYF cells rarely exhibited the 
actin cap (2 ± 2%) (Fig. 3.5B and D) and treatment with 0.5 mM Na3VO4 for 1 h did not so much 
increase numbers of SYF cells exhibiting the actin cap (11 ± 3%) (Fig. 3.5B and D), indicating 
that the lack of SFK activity results in low levels of actin cap formation. Next, we examined 
actin cap formation in SYF cells transfected with c-Src or Lyn, and protein expression of c-Src 
and Lyn was confirmed by Western blotting (Fig. 3.5A). Lyn expression resulted in an 
approximately 3-fold increase in numbers of cells exhibiting the actin cap, although c-Src 
expression did not increase numbers of cells exhibiting the actin cap (Fig. 3.5C and D). These 
results suggest that Lyn can preferentially mediate actin cap formation. 
 
Inhibition of actin cap formation by dominant-negative Lyn constructs 
Excess induction of the SH2 or SH3 domain of SFKs inhibits functions of endogenous 
SFKs in various events, including G2/M-phase cell cycle transition, cytokinesis, transcriptional 
activation, and calcium release during fertilization [16,18,19,98]. To examine the involvement of 
 36 
endogenous Lyn in actin cap formation in HeLa cells, we performed transfection experiments 
with Lyn∆K-HA that preserves the SH2 and SH3 domains but lacks the kinase domain [32] (Fig. 
3.6A). Transfection with Lyn∆K-HA inhibited actin cap formation, whereas transfection with 
nothing or intact Lyn did not affect actin cap formation (% cells exhibiting the actin cap: nothing, 
90 ± 5%; intact Lyn, 84 ± 3%; Lyn∆K, 60 ± 6%) (Fig. 3.6B and C). Next, HeLa cells were 
transfected with SH2- or SH3-deleted Lyn∆K-HA (Lyn∆K∆SH2-HA or Lyn∆K∆SH3-HA) (Fig. 
3.6A). In fact, Lyn∆K∆SH3-HA could not inhibit actin cap formation, whereas 
Lyn∆K∆SH2-HA retained the inhibitory effect (% cells exhibiting the actin cap: 
Lyn∆K∆SH2-HA, 51 ± 8%; Lyn∆K∆SH3-HA, 84 ± 6%) (Fig. 3.6B and C). Inhibition of actin 
cap formation was also shown in cells transfected with Lyn118-GFP, which is composed of the 
SH4, unique, and SH3 domains of Lyn and the GFP-tag (% cells exhibiting the actin cap: 59 ± 
6%) (Fig. 3.6A–C). These results suggest that the Lyn SH3 domain exerts a dominant-negative 
effect on actin cap formation. 
To further confirm the inhibitory effect of the Lyn SH3 domain on actin cap formation, 
alanine mutation of Trp99 was introduced into Lyn118-GFP [Lyn118(W99A)-GFP] (Fig. 3.6A). 
Trp99 of Lyn is the conserved tryptophan in SH3 domains, which is a critical for ligand binding 
of SH3 domains [99–102]. Fig. 3.6B and C shows that Lyn118(W99A)-GFP could not inhibit 
actin cap formation (% cells exhibiting the actin cap: 87 ± 7%). These results suggest that the 
Lyn SH3 domain inhibits actin cap formation through its ligand binding.  
 
 
Discussion 
The actin cap, a massively accumulated structure of actin filaments at the cell top, is stably 
formed in HeLa cells. In the present study, we show that SFKs play an important role in 
formation of the actin cap. The kinase activity of SFKs is required for actin cap formation 
through an increase in SFK-mediated tyrosine phosphorylation. Lyn, an SFK member, is in 
particular involved in actin cap formation. 
SFKs are known to phosphorylate and activate various proteins, including actin assembly 
regulators [1,2,78,79]. The actin cap seen in HeLa cells is disrupted by treatment with PP2 or 
SU6656 (Fig. 3.2), suggesting that the activity of SFKs is required for actin cap formation. 
Because actin stress fibers are not disrupted by inactivation of SFKs (Figs. 3.2–4), SFKs 
preferentially regulate formation of the actin cap. In contrast to HeLa cells, Csk-knockout D5 
cells minimally form the actin cap (Figs. 3.3 and 3.4). Treatment of D5 cells with Na3VO4, which 
increases tyrosine phosphorylation of intracellular proteins through inhibition of PTP activity 
(Fig. 3.3), leads to formation of the actin cap (Figs. 3.3–3.5), and Na3VO4-induced formation of 
the actin cap is inhibited by inactivation of SFKs with PP2 or inducible Csk expression (Figs. 3.3 
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and 3.4). Given that protein-tyrosine phosphorylation is reciprocally regulated by PTKs and 
PTPs [69–71], these results suggest that actin cap formation is regulated by tyrosine 
phosphorylation/dephosphorylation of SFK substrates. 
SYF cells are genetically deficient in expression of c-Src, c-Yes, and Fyn and do not 
express Lyn at a detectable level [77]. SYF cells minimally exhibit the actin cap even in the 
presence of Na3VO4 (Fig. 3.5). Intriguingly, transfection of SYF cells with Lyn restores 
formation of the actin cap in the presence of Na3VO4 (Fig. 3.5). Furthermore, the actin cap 
present in HeLa cells is disrupted by expression of three dominant-negative Lyn constructs (Fig. 
3.6). Taken together with the findings that kinase-active Lyn and the dominant-negative 
constructs are localized to the actin cap (Supplementary Fig. 3.3, and data not shown), these 
results suggest that Lyn recruited to the actin cap plays an important role in actin cap formation. 
Overlapping expression of endogenous Lyn, c-Src, c-Yes, and Fyn is observed in various 
cell types, including HeLa cells [1,2,72], and these SFK members are shown to exhibit 
redundancy in their activation and functions [1,2,18,72,74,77]. We observed by 
immunofluorescence that c-Src, c-Yes, and Fyn besides Lyn are localized to the actin cap in 
HeLa cells (data not shown). We therefore imagine that multiple SFK members can contribute to 
actin cap formation. However, re-introduction of c-Src into SYF cells cannot restore formation 
of the actin cap (Fig. 3.5), suggesting that c-Src per se may not be involved in actin cap 
formation. In addition, Na3VO4 treatment of SYF cells results in modest induction of actin cap 
formation without transfection with SFKs (Fig. 3.5), suggesting that PTKs other than SFKs may 
also contribute to actin cap formation. 
The actin cytoskeleton provides docking sites for proteins involved in intracellular signal 
transduction [80,97,103–105]. The actin cap is one of the major sites of tyrosine phosphorylation 
(Fig. 3.1), and tyrosine phosphorylation at the actin cap increases upon epidermal growth factor 
stimulation (Supplementary Fig. 3.4), suggesting that the actin cap functions as a platform for 
tyrosine phosphorylation signal transduction. The actin cap morphologically changes into the 
cortical actin cytoskeleton that covers the cell cortex of mitotic round-cells during G2- to 
M-phase cell cycle transition (Supplementary Fig. 3.1) where the kinase activity of SFKs 
increases [13,18,72], suggesting that the actin cap also acts as filament nucleation for 
development of the mitotic actin cytoskeleton. The actin cap may therefore contribute to cell 
proliferation and cell division. 
In conclusion, our results show that SFK-mediated tyrosine phosphorylation plays an 
important role in actin cap formation. SFKs may act on the regulation of intracellular signal 
transduction and the development of the mitotic cytoskeleton through actin cap formation. To 
elucidate the mechanism of actin cap formation, it is necessary to identify SFK substrates and 
PTPs that regulate actin cap formation. It will be valuable to search Lyn substrates that are 
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localized to the actin cap via a direct or indirect association with the Lyn SH3 domain, because 
Lyn contributes to actin cap formation through its SH3 domain (Fig. 3.6). Characterization of the 
signal transduction pathway through SFKs leading to actin cap formation can help us understand 
the physiological roles of the actin cap above the nucleus in spread cells such as epithelial and 
fibroblastic cells. 
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Figures 3 
 
Fig. 3.1. Visualization of tyrosine phosphorylation at the actin cap. 
(A, B) HeLa cells treated (B, Na3VO4) or untreated (A and B, control) with 0.1 mM Na3VO4 for 
5 min were stained with anti-phosphotyrosine (pTyr) antibody for tyrosine phosphorylation 
(green) and rhodamine-phalloidin for F-actin (red). Confocal slice images at the bottom and top 
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of representative cells are shown. Yellow outlines indicate cell borders. The image of the actin 
cap at high magnification is shown (A, right). (C) HeLa cells were stained for F-actin (red). 
Z-series sections at 1.0-µm intervals (Z axis) from the bottom (0 µm) to the top (7.0 µm) of a 
representative cell are shown. Z-series sections at 0.5-µm intervals from the bottom (0 µm) to the 
top (7.0 µm) of the cell are merged in a two-dimensional image (XY). Orthogonal sections 
viewing axial directions (XZ and YZ) are created in the margins. (D) HeLa cells were stained for 
F-actin (red) and DNA (blue). Confocal slice images at the bottom, middle, and top of a 
representative cell are shown. A two-dimensional image (XY) generated from Z-series sections 
at 0.5-µm intervals and orthogonal sections viewing axial directions (XZ and YZ) are shown 
(right). Arrows indicate the actin cap. Scale bars, 10 µm. 
 
 
Fig. 3.2. Disruption of the actin cap by SFK inhibitors. 
(A) HeLa cells treated with DMSO (solvent control) or 10 µM PP2 for 1 h were stained with 
anti-pTyr antibody for tyrosine phosphorylation (green) and rhodamine-phalloidin for F-actin 
(red). Confocal slice images at the top of cells are shown. (B) HeLa cells treated with DMSO 
(control) or 10 µM PP2 for 30 min were stained for F-actin (red). Confocal slice images at the 
bottom and top of cells are shown. Yellow outlines indicate borders of cells exhibiting the actin 
cap, and dotted outlines indicate borders of cells that did not exhibit the actin cap. Scale bars, 10 
µm. (C, D) The bar diagrams show percentages of HeLa cells exhibiting the actin cap after 
treatment with the indicated concentrations of PP2 (C) or SU6656 (D) for 30 min. Data are 
expressed as mean ± SD from three independent experiments (n > 100 for each experiment). 
Asterisks indicate significant differences from controls (left bars), calculated by Student′s t-test 
(***p < 0.001). 
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Fig. 3.3. Actin cap formation induced by Na3VO4 and inhibited by PP2. 
D5 cells were treated (+) or untreated (-) with 0.5 mM Na3VO4 for 1 h in the presence (+) or 
absence (-) of 10 µM PP2 one hour before Na3VO4 treatment. (A) Cell lysates were analyzed by 
Western blotting with anti-pTyr antibody for tyrosine-phosphorylated proteins and 
anti-Src[pY418] antibody for active SFKs. Levels of active SFKs are normalized to the expression 
of α-tubulin (loading control) and are expressed relative to the level in control cells (left lane). 
(B) Cells were stained with anti-pTyr antibody for tyrosine phosphorylation (green) and 
rhodamine-phalloidin for F-actin (red). Confocal slice images at the bottom and top of cells are 
shown. Yellow outlines indicate borders of cells exhibiting the actin cap, and dotted outlines 
indicate borders of cells that did not exhibit the actin cap. Cells became slightly round upon 
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Na3VO4 treatment. Scale bars, 10 µm. (C) The bar diagram shows percentages of D5 cells 
exhibiting the actin cap in the presence (+) or absence (-) of Na3VO4. (D) Comparison of 
percentages of Na3VO4-treated cells exhibiting the actin cap between the presence (+) and 
absence (-) of PP2. Data represent mean ± SD from three independent experiments (n > 100 for 
each experiment) (C, D). Asterisks indicate significant differences (+p < 0.1, **p < 0.01) 
calculated by Student′s t-test.  
 
 
Fig. 3.4. Inhibition of actin cap formation by inducible Csk expression. 
(A) D5, D5/Csk32-5, and NIH3T3 cells were cultured in the presence (+) or absence (-) of 1 
µg/ml doxycycline (Dox) for 2 days. Expression of endogenous Csk and inducible Csk-HA was 
examined by Western blotting with anti-Csk, anti-HA, and anti-α-tubulin (loading control) 
antibodies. (B) D5/Csk32-5 cells were cultured in the presence (+) or absence (-) of 1 µg/ml Dox 
for 2 days and then treated (+) or untreated (-) with 0.5 mM Na3VO4 for 1 h. Cell lysates were 
analyzed for inducible expression of Csk-HA using anti-HA antibody and levels of active SFKs 
using anti-Src[pY418] antibody, as described in Fig. 3.3A. (C) The bar diagram shows 
percentages of D5/Csk32-5 cells exhibiting the actin cap upon treatment with (+) or without (-) 
0.5 mM Na3VO4 for 1 h. (D, E) D5/Csk32-5 cells cultured in the presence (+) or absence (-) of 1 
µg/ml Dox for 2 days were treated with 0.5 mM Na3VO4 for 1 h. (D) Cells were stained for 
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F-actin (red). Confocal slice images at the bottom and top of cells are shown. Yellow outlines 
indicate borders of cells exhibiting the actin cap, and dotted outlines indicate borders of cells that 
did not exhibit the actin cap. Cells became slightly round upon Na3VO4 treatment. Scale bars, 10 
µm. (E) Comparison of percentages of Na3VO4-treated cells exhibiting the actin cap between the 
presence (+) and absence (-) of Dox. Data represent mean ± SD from three independent 
experiments (n ≥ 100 for each experiment) (C, E). Asterisks indicate significant differences (*p 
< 0.05, **p < 0.01) calculated by Student′s t-test.  
 
 
Fig. 3.5. Actin cap formation mediated by Lyn. 
(A) SYF cells transfected with c-Src, Lyn, or control vector were cultured for 24 h. Cell lysates 
were analyzed by Western blotting with anti-Src, anti-Lyn, and anti-α-tubulin (loading control) 
antibodies. (B–D) SYF cells transfected with c-Src (C, D), Lyn (C, D), or control vector (B, D) 
were cultured for 24 h and then treated (+) or untreated (-) with 0.5 mM Na3VO4 for 1 h.  
 44 
(B, C) Cells were stained for F-actin (red) and c-Src or Lyn (green). Confocal slice images at the 
bottom and top of cells are shown. Yellow outlines indicate borders of cells exhibiting the actin 
cap, and dotted outlines indicate borders of cells that did not exhibit the actin cap. Scale bars, 10 
µm. (D) The bar diagram shows percentages of cells that exhibit the actin cap. Data represent 
mean ± SD from three independent experiments (n > 100 for each experiment). Asterisks 
indicate significant differences (*p < 0.05) calculated by Student′s t-test (NS, not significant). 
 
 
Fig. 3.6. Disruption of the actin cap by the Lyn SH3 domain. 
(A) Schematic representations of Lyn and its mutants are shown with the Src homology (SH) 
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domains, the alanine mutation of Trp99 (circled A), the HA-epitope tag, and the GFP tag. (B, C) 
HeLa cells were transfected with Lyn, Lyn mutants, or none and then cultured for 24 h. (B) Cells 
were stained with rhodamine-phalloidin for F-actin (red), anti-Lyn antibody for intact Lyn, 
anti-HA antibody for Lyn∆K-HA, Lyn∆K∆SH2-HA and Lyn∆K∆SH3-HA. Lyn118-GFP and 
Lyn118(W99A)-GFP were visualized by fluorescence of GFP. Confocal slice images at the 
bottom and top of cells are shown. Yellow outlines indicate borders of cells exhibiting the actin 
cap, and dotted outlines indicate borders of cells that did not exhibit the actin cap. Scale bars, 10 
µm. (C) The bar diagram shows percentages of cells that exhibit the actin cap. Data represent 
mean ± SD from three independent experiments (n > 100 for each experiment). Asterisks 
indicate significant differences (*p < 0.05, **p < 0.01, ***p < 0.001) calculated by Student′s 
t-test (NS, not significant). 
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Supplementary Figures 3 
 
Supplementary Fig. 3.1. Actin cap formation throughout the cell cycle. 
(A) HeLa cells were stained for F-actin (red) and cyclin B1 (green). Confocal slice images at the 
bottom and top of cells are shown. Yellow outlines indicate cell borders. (B) HeLa cells were 
co-transfected with mCherry-β-actin (red) and histone H2B-GFP (green, H2B-GFP). Living cells 
were monitored at the indicated intervals during cell cycle transition from prometaphase 
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(00’00”) to metaphase (50’00”). Chromatin was condensed and aligned at metaphase plate 
during the cell cycle transition. A representative result is shown. Arrows indicate the actin cap. 
Scale bar, 10 µm. 
 
 
Supplementary Fig. 3.2. Nomarski image of the actin cap. 
HeLa cells were stained for F-actin (red). A confocal slice image focusing the actin cap and the 
corresponding Nomarski image are shown. A representative result is shown. Scale bar, 10 µm. 
 
 
Supplementary Fig. 3.3. Visualization of kinase-active Lyn. 
HeLa cells were transfected with Lyn and stained with anti-Lyn antibody for expressed Lyn 
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(green) and anti-Src[pY418] for kinase-active Lyn (red). Confocal slice images at the bottom and 
top of a representative cell are shown. The squared areas are magnified (right). Actin cap-like 
staining of Lyn mostly overlaps active Lyn at the cell top. Scale bar, 10 µm. 
 
 
Supplementary Fig. 3.4. An increase in tyrosine phosphorylation at the actin cap upon 
EGF stimulation. 
HeLa cells were treated (EGF treatment) or untreated (control) with 50 ng/ml epidermal growth 
factor (EGF) for 1 min after serum starvation for 12 h. Cells were stained with anti-pTyr 
antibody for tyrosine phosphorylation (green) and rhodamine-phalloidin for F-actin (red). 
Confocal slice images at the bottom and top of cells are shown. The actin cap of an 
EGF-stimulated cell is shown at high magnification (right). Yellow outlines indicate cell borders. 
Scale bars, 10 µm.  
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